Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90° (VAIIO)
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
VSL#3 active probiotic
VSL#3 placebo
Sponsored by

About this trial
This is an interventional supportive care trial for Obesity focused on measuring probiotic, obesity, BMI, metabolic profile, metabolomics
Eligibility Criteria
Inclusion Criteria:
- age 6-12
- parents or tutors able to give the written consent and follow the study procedures Value of BMI>90°
Exclusion Criteria:
- - Any severe or concomitant clinical or psychiatric condition that, in the investigator's opinion, could affect the treatment, the evaluations and the inclusion in the protocol;
- Evidence of active liver disease due to other causes;
- Steroid treatment; immuno suppressive therapies, chemotherapy agents within 2 month from screening;
- Pregnancy or breastfeeding;
- Abuse of alcohol and drugs clinically relevant;
- Diabetes.
Sites / Locations
- Bambino Gesù Children Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
VSL#3 placebo
VSL#3 active probiotic
Arm Description
The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
Outcomes
Primary Outcome Measures
Evaluate the effects of VSL#3 on metabolic, endocrine, lipidomic, metabolomic and inflammatory markers and microbiota variation of pediatric patients with BMI>90°
Secondary Outcome Measures
Full Information
NCT ID
NCT01650025
First Posted
July 23, 2012
Last Updated
January 30, 2017
Sponsor
Bambino Gesù Hospital and Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT01650025
Brief Title
Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°
Acronym
VAIIO
Official Title
Effects of the Probiotic Preparation VSL#3 on the Metabolic, Endocrine, Lipidomic and Inflammatory Parameters as Well as Variation of the Microbiota in Pediatric Patients With Body Mass Index >90°
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bambino Gesù Hospital and Research Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Obesity in children has become a significant social problem considering that nowadays 4 to 5 % of all children are obese in the industrialized countries with increased incidence in Europe by 10 to 50% over the past 10 years. Obesity is associated with the metabolic syndrome in 30% of the children and is considered as a state of chronic inflammation inducing the production of pro-inflammatory cytokines which determine metabolic and endocrine alterations on the organism. It has been observed that obesity is also linked to a change in the intestinal microflora with a reduction of Bacterioides and bifidobacteria and a decrease of Firmicutes and Staphylococcus aureus. The qualitative and quantitative analysis of the metabolites may provide us with a characterization of the existing phenotypes and variations in relation to the changes of the physiological state, in particular when supplemented or not with a probiotic preparation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
probiotic, obesity, BMI, metabolic profile, metabolomics
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
VSL#3 placebo
Arm Type
Placebo Comparator
Arm Description
The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
Arm Title
VSL#3 active probiotic
Arm Type
Active Comparator
Arm Description
VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
Intervention Type
Dietary Supplement
Intervention Name(s)
VSL#3 active probiotic
Other Intervention Name(s)
VSL#3
Intervention Type
Other
Intervention Name(s)
VSL#3 placebo
Other Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Evaluate the effects of VSL#3 on metabolic, endocrine, lipidomic, metabolomic and inflammatory markers and microbiota variation of pediatric patients with BMI>90°
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age 6-12
parents or tutors able to give the written consent and follow the study procedures Value of BMI>90°
Exclusion Criteria:
- Any severe or concomitant clinical or psychiatric condition that, in the investigator's opinion, could affect the treatment, the evaluations and the inclusion in the protocol;
Evidence of active liver disease due to other causes;
Steroid treatment; immuno suppressive therapies, chemotherapy agents within 2 month from screening;
Pregnancy or breastfeeding;
Abuse of alcohol and drugs clinically relevant;
Diabetes.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerio Nobili, PhD
Organizational Affiliation
Bambino Gesù Children Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bambino Gesù Children Hospital
City
Rome
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
24738701
Citation
Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014 Jun;39(11):1276-85. doi: 10.1111/apt.12758. Epub 2014 Apr 16.
Results Reference
derived
Learn more about this trial
Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°
We'll reach out to this number within 24 hrs